Borsi Seyed Hamid, Rashidi Homeira, Shaabanpour Maryam, Raji Hanieh
Ahvaz Jundishapur University of Medical Sciences.
Monaldi Arch Chest Dis. 2018 Feb 19;88(1):892. doi: 10.4081/monaldi.2018.892.
Asthma is an inflammatory disease, which causes airflow limitation and increase insulin resistance. The present study was carried out in order to investigate insulin resistance and the effect of inhaled corticosteroid (ICS) on insulin sensitivity in asthmatic patients. A registered (IRCT201605247411N2) interventional, quasi-experimental trial was performed from 2014 to 2015 in Imam Khomeini hospital Ahvaz, Iran. Patients with mild to moderate asthma participated in this study. Spirometry, fasting blood sugar (FBS), blood sugar 2 hour post prandial (BS2HPP), HbA1C, low density lipoprotein (LDL), high density lipoprotein (HDL), Insulin Level, and C reactive protein (CRP) were measured. Then Homeostatic Model Assessment-Insulin Resistance [HOMA-IR] Index calculated. Data were analyzed using paired t-test and McNemar's test using SPSS 20.0 Software. The study consisted of 35 non-diabetic patients suffering from asthma (20 men and 15 women) with a mean age of 36.6 ±12.3 years. Inhaled corticosteroid had a significant effect on spirometric parameters, but it had no significant effect on other variables. At baseline, mean HbA1C, insulin level and HOMA-IR were 5.5%, 10.9 mIU/L and 2.7 respectively. None of these values changed significantly after treatment with inhaled corticosteroid for two months. The results indicated that there is no relationship between ICS and increased insulin resistance in asthmatic patients.
哮喘是一种炎症性疾病，可导致气流受限并增加胰岛素抵抗。本研究旨在调查哮喘患者的胰岛素抵抗情况以及吸入性糖皮质激素（ICS）对胰岛素敏感性的影响。2014年至2015年在伊朗阿瓦士的伊玛目霍梅尼医院进行了一项注册（IRCT201605247411N2）干预性、准实验性试验。轻度至中度哮喘患者参与了本研究。测量了肺活量、空腹血糖（FBS）、餐后2小时血糖（BS2HPP）、糖化血红蛋白（HbA1C）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、胰岛素水平和C反应蛋白（CRP）。然后计算稳态模型评估-胰岛素抵抗[HOMA-IR]指数。使用SPSS 20.0软件通过配对t检验和 McNemar检验对数据进行分析。该研究包括35名非糖尿病哮喘患者（20名男性和15名女性），平均年龄为36.6±12.3岁。吸入性糖皮质激素对肺活量参数有显著影响，但对其他变量无显著影响。基线时，平均HbA1C、胰岛素水平和HOMA-IR分别为5.5%、10.9 mIU/L和2.7。吸入性糖皮质激素治疗两个月后，这些值均无显著变化。结果表明，ICS与哮喘患者胰岛素抵抗增加之间没有关系。
